Millions of Brazilians with private health plans have been denied coverage for Mounjaro. A TJ/SP ruling may have shifted the legal landscape. Learn what it means for you.
Millions of Brazilians with private health plans have been denied coverage for Mounjaro (tirzepatide), one of the most effective medications available today for type 2 diabetes and weight management. A recent ruling from the São Paulo Court of Justice (TJ/SP) may have changed that landscape significantly. For the approximately 51 million Brazilians with private health insurance according to ANS data, understanding this decision could be the key to finally getting the treatment their physician prescribed.
You'll learn how this ruling works, what it means legally, how to use it when requesting coverage from your health plan, and what limitations still exist.
What Is Mounjaro and Why Are Health Plans Denying Coverage?
Mounjaro contains the active ingredient tirzepatide, a dual GIP/GLP-1 receptor agonist approved by ANVISA for the treatment of type 2 diabetes. This medication works by mimicking two gut hormones that help regulate blood sugar and appetite, leading to significant improvements in glycemic control and weight loss in clinical settings. Beyond its diabetes indication, tirzepatide has shown remarkable results for obesity management, which has driven enormous patient interest.
The core reason health plans deny coverage is straightforward: Mounjaro is not on the ANS mandatory coverage list, known as the Rol de Procedimentos e Eventos em Saúde. This list establishes the minimum procedures and medications that all health plans must cover in Brazil. Currently, the ANS Rol typically covers older antidiabetic medications including metformin, sulfonylureas, insulin, and certain GLP-1 agonists like semaglutide when specific clinical criteria are met. Tirzepatide, despite its effectiveness, remains outside this list.
Patients face a frustrating administrative burden. Multiple denial letters, appeals processes that stretch across months, and out-of-pocket costs that can reach significant levels make accessing this medication extremely challenging for many Brazilians.
The TJ/SP Decision: What Actually Happened
São Paulo's Court of Justice has emerged as a critical venue for health plan disputes in Brazil, handling one of the highest volumes of such cases in the country. Recent decisions from this court have addressed a fundamental legal question: whether health plans can be compelled to cover medications not explicitly listed on the ANS Rol when those medications are prescribed for medically necessary conditions supported by clinical evidence.
The legal principle at the center of these cases stems from Article 196 of the Brazilian Constitution, which establishes health as a universal right and places the obligation to ensure access on the State. Courts have increasingly recognized that while the ANS Rol establishes minimum coverage standards, it cannot serve as an absolute barrier to treatments that physicians determine are medically necessary for their patients.
The Legal Basis Behind the Ruling
Law 9.656/1998, known as the Lei dos Planos de Saúde, establishes the framework for minimum coverage requirements in Brazil's private health insurance sector. However, legal doctrine and judicial interpretation have consistently held that the ANS Rol represents a floor, not a ceiling, for coverage obligations.
This interpretation allows courts to order coverage of medications not explicitly listed when three conditions are met: the medication is prescribed for a covered condition, clinical evidence supports its use, and the prescribing physician provides adequate medical justification. The role of medical evidence cannot be overstated in these cases. Documented clinical need, detailed physician prescriptions specifying the medical rationale, and evidence of prior treatment failures with covered alternatives have been central to successful court claims.
This approach has created a growing body of case law favoring coverage of innovative medications that demonstrate clear clinical benefit, particularly for patients with conditions like obesity, type 2 diabetes, and associated cardiovascular risk factors.
What This Means for Patients Currently Seeking Coverage
The TJ/SP ruling and similar decisions provide significant legal ammunition for patients fighting for Mounjaro coverage. You can now cite these precedents in coverage requests and administrative appeals, strengthening arguments that health plans cannot categorically deny treatments based solely on ANS Rol exclusion.
However, realistic expectations matter. The ruling strengthens legal arguments but does not automatically guarantee coverage for every patient. These decisions apply most strongly to patients with documented comorbidities such as obesity, type 2 diabetes, or cardiovascular risk factors where tirzepatide has demonstrated clear clinical benefit. Single-episode or preference-based requests face higher hurdles.
Be prepared for time investment. Judicial or administrative processes for health plan disputes typically take months to resolve, and multiple rounds of appeals may be necessary before reaching a final decision.
Step-by-Step: How to Request Mounjaro Coverage Using This Legal Framework
Start by obtaining a detailed medical prescription from your physician. This document should specify your clinical indication, expected treatment outcomes, and explicit justification for why alternatives currently on the ANS Rol are insufficient for your case.
Submit a formal coverage request to your health plan in writing. Keep copies of everything and maintain proof of delivery through registered mail or digital confirmation. If your request is denied, request the specific legal and medical basis for denial in writing before proceeding.
File an appeal with your health plan's internal grievance committee. Reference the TJ/SP ruling and emphasize your constitutional right to health under Article 196. If internal appeals fail, you have several options: file a complaint with PROCON, seek assistance from consumer protection agencies, or proceed to judicial channels. For disputes involving amounts under 40 minimum wages, the Juizado Especial Cível offers an accessible forum without the need for an attorney.
Limitations and What the Ruling Does Not Solve
The TJ/SP decision applies to specific case types and circumstances. Not every patient scenario will qualify, and health plans will continue contesting coverage in many situations. Plan type matters significantly. Self-funded plans may have different obligations compared to employer-sponsored or collective plans, and legal strategies must account for these distinctions.
Medical necessity documentation remains non-negotiable. Courts and health plans require robust clinical justification demonstrating medical need, not merely patient preference for a particular medication. Even with coverage approved, pharmacy availability and distribution challenges can create practical barriers to actually obtaining the medication.
The Bigger Picture: Innovation, Coverage, and Patient Access in Brazil
Coverage gaps for innovative medications reflect a structural lag. Regulatory approval, clinical evidence accumulation, and ANS list updates move at different paces, creating periods where effective treatments exist but remain inaccessible through health plans. Health insurers cite pricing and budget impact as justifications for exclusions, though patients and advocates argue that long-term health benefits and reduced complications often offset initial treatment costs.
Patient advocacy organizations and legal aid services are increasingly helping Brazilians navigate coverage disputes. Monitoring potential ANS updates, new judicial decisions, and legislative discussions will be important for anyone seeking to understand how coverage rights may evolve.
For more updates on tirzepatide access, coverage decisions, and clinical guidance, bookmark the TirzeBlog. The team regularly tracks regulatory changes and medical recommendations that affect patients using these medications.
Patients are not powerless against health plan denials. Understanding your legal rights, maintaining thorough medical documentation, and working closely with your physician gives you the best possible chance of getting the treatment you need.
FAQ
Can private health plans in Brazil be forced to cover Mounjaro?
Under certain circumstances, yes. Courts including the TJ/SP have ruled that health plans cannot categorically deny coverage for medications not on the ANS Rol when medically necessary and supported by clinical evidence. Success depends on strong medical documentation and proper legal procedure.
What is the ANS Rol and how does it affect Mounjaro coverage?
The ANS Rol de Procedimentos e Eventos em Saúde is the mandatory coverage list that establishes minimum standards for private health plans in Brazil. Medications not on this list can still be covered through judicial orders when medically justified, but the exclusion creates an additional barrier patients must overcome.
What documentation do I need to request Mounjaro coverage?
You need a detailed medical prescription specifying the clinical indication, justification for why covered alternatives are insufficient, and expected treatment outcomes. Medical history documentation, proof of prior treatment failures with covered medications, and any relevant test results strengthening your case are essential.
Does the TJ/SP ruling apply to all health plans in Brazil?
The ruling specifically addresses cases within São Paulo jurisdiction and sets important precedent, but its application varies by plan type, specific circumstances, and other regional courts may interpret similar issues differently. Consulting with a legal professional familiar with health plan disputes is advisable.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Track your weight and your progress
Log weight, measurements and labs and see your progress in clear charts — because progress you don't measure is invisible progress.
or download the app
